Strategic Acquisition Aluna recently attracted significant strategic attention with Huma Therapeutics acquisition interest and expansion in the US, signaling a potential for partnership or co-selling opportunities in respiratory health management across geographies.

Growth Funding With a combined funding of around 21 million and a Series B closure, there is budgetary readiness for enterprise partnerships, larger pilot programs, and potential integration projects with clinic networks and EHR platforms.

Healthcare Integration Partnerships with ModuleMD and the at home spirometer platform indicate a strong open pathway for integration with EHRs and practice management systems, suggesting opportunities to cross-sell connectors, data interoperability, and referral workflows.

Clinical Impact The product focus on chronic respiratory management and asthma monitoring positions Aluna well for hospitals, clinics, and specialist pulmonology providers seeking remote patient monitoring, AI-driven insights, and adherence support solutions.

Market Momentum A diverse tech stack and active product/brand presence including recent media coverage and a notable investor base imply readiness for scaled deployments, channel partnerships, and enterprise pilots in medical equipment and digital health arenas.